

אוקטובר 2021

# הודעה על עדכון עלונים: Gendevra film coated tablets

### (elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide fumarate)

רופאים ורוקחים נכבדים,

חברת גיליאד סיאנסז ישראל בע"מ מבקשת להודיעכם על עדכון בעלון לרופא ובעלון לצרכן של התכשיר בנדון.

#### ההתוויה הרשומה לתכשיר בישראל:

Gendevra is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir as follows:

- In adults and adolescents aged from 12 years and with body weight at least 35 kg
- In children aged from 6 years and with body weight at least 25 kg for whom alternative regimens are unsuitable due to toxicities.

השינויים מסומנים בעלון המצורף כאשר הטקסט המודגש <mark>באדום</mark> הוסף לעלון ואילו הטקסט המחוק <del>בקו חוצה</del> נגרע ממנו. הסימונים <mark>בצהוב</mark> הינם החמרות במידע הבטיחותי.

לעדכון עלונים זה מצורף מכתב לצוות הרפואי.

העדכונים המשמעותיים ביותר מופיעים במכתב זה, קיימים עדכונים מינוריים נוספים.

העלונים לרופא ולצרכן נשלחו לפרסום במאגר התרופות שבאתר משרד הבריאות:

https://data.health.gov.il/drugs/index.html#/byDrug

כמו כן ,ניתן לקבלם מודפסים על ידי פנייה לבעל הרישום:

גיליאד סיאנסז ישראל בע"מ, רחוב החרש 4 ,ת.ד. 6090, פארק העסקים הוד השרון 4524075,

ישראל

בברכה.

מריה חורגין

רוקחת ממונה

גיליאד סיאנסז ישראל בע"מ

# העדכונים המהותיים בעלון לרופא:

# 4.5 Interaction with other medicinal products and other forms of interaction

. . .

Table 1: Interactions between the individual components of Gendevra and other medicinal products

| Medicinal product  | Effects on medicinal    | Recommendation concerning co-administration with                 |
|--|-------------------------|--|
| by therapeutic areas   | product levels.         | Gendevra   |
|  | Mean percent            |  |
|  | change in AUC,          |  |
|  | Cmax, Cmin <sup>1</sup> |  |
| GLUCOCORTICOIDS  |                         |  |
| All corticosteroids excluding cutaneous products Corticosteroids |                         |  |
| Corticosteroids  | Interaction not         | Concomitant use of Gendevra and corticosteroids that are         |
| primarily metabolised  | studied with any of     | metabolised by CYP3A (e.g. fluticasone propionate or other       |
| by CYP3A (including  | the components of       | inhaled or nasal corticosteroids) may increase the risk of       |
| betamethasone,   | Gendevra.               | development of systemic corticosteroid effects, including        |
| budesonide,  |                         | Cushing's syndrome and adrenal suppression.                      |
| fluticasone,   | Plasma                  |  |
| mometasone,  | concentrations of       | Co-administration with CYP3A-metabolised corticosteroids is      |
| prednisone,  | these medicinal         | not recommended unless the potential benefit to the patient      |
| triamcinolone).  | products may be         | outweighs the risk, in which case patients should be monitored   |
|  | increased when          | for systemic corticosteroid effects. Alternative corticosteroids |
|  | co-administered with    | which are less dependent on CYP3A metabolism e.g.                |
|  | Gendevra, resulting     | beclomethasone for intranasal or inhalational use should be      |
|  | in reduced serum        | considered, particularly for long-term use.                      |
|  | cortisol                |  |
|  | concentrations.         | For coadministration of cutaneously-administered                 |
|  |                         | corticosteroids sensitive to CYP3A inhibition, refer to the      |
|  |                         | prescribing information of the corticosteroid for conditions or  |
|  |                         | uses that augment its systemic absorption.                       |

# 6.1 List of excipients

### Tablet core

Microcrystalline cellulose <u>(E460)</u> Croscarmellose sodium Lactose (as monohydrate) Sodium lauryl sulfate Magnesium stearate Hydroxypropyl cellulose <u>(E463)</u> Silicon dioxide <u>(E551)</u>

#### Film-coating

Polyvinyl alcohol (E1203)
Titanium dioxide (E171)
Polyethylene glycol (E1521)
Talc (E553b)
Indigo carmine aluminium lake (E132)
Iron oxide yellow (E172)
...

6.3

Shelf life

The expiry of the product is indicated on the packaging materials.

After first opening, use within 30 days.

2

# העדכונים המהותיים בעלון לרופא:

#### 2. Before taking Gendevra

#### Other medicines and Gendevra

...

Talk to your doctor if you are taking:

...

- corticosteroids including:
  - betamethasone, budesonide, fluticasone, mometasone, prednisone, triamcinolone. These medicines are used to treat allergies, asthma, inflammatory bowel diseases, inflammatory conditions of the <a href="skin">skin</a>, eyes, joints and muscles and other inflammatory conditions. <a href="These">These</a> medicines are generally taken orally, inhaled, injected or applied to the skin or eye. If alternatives cannot be used, its use should only take place after medical evaluation and under close monitoring by your doctor for corticosteroid side effects.

# 5. How to store Gendevra

...

Do not use this medicine after the expiry date which is stated on the carton and bottle after {EXP}. The expiry date refers to the last day of that month. After first opening, use within 30 days.

#### 6. Additional Information

#### What Gendevra contains

In addition to the active ingredients Gendevra contains:

#### Tablet core:

Microcrystalline cellulose (E460), croscarmellose sodium, lactose (as monohydrate), sodium lauryl sulfate, magnesium stearate, hydroxypropyl cellulose (E463), silicon dioxide (E551).

#### *Film-coating:*

Polyvinyl alcohol (E1203), titanium dioxide (E171), polyethylene glycol (E1521), talc (E553b), indigo carmine aluminium lake (E132), iron oxide yellow (E172).